SCHEMBL175063

SCHEMBL175063

Cc1ccc(N(CC=CO)CC=CO)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
TSHR P16473 2/20 0.44
CYP2C19 P33261 1/20 0.42
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
MAPT P10636 4/20 0.34
HTT P42858 3/20 0.34
KDM4E B2RXH2 4/20 0.33
TDP1 Q9NUW8 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
RAB9A P51151 1/20 0.33
ACHE P22303 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CA2 P00918 1/20 0.33
LPL P06858 1/20 0.33
LIPG Q9Y5X9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7047586 0.91 CNR1 (0.41) ALDH1A1TSHRCYP2C19LMNAPOLB
SCHEMBL16299004 0.81 ALDH1A1 (0.46) ALDH1A1TSHRCYP2C19LMNAPOLB
SCHEMBL90526 0.79 ALDH1A1 (0.33) ALDH1A1
SCHEMBL11466649 0.79 ALDH1A1 (0.48) ALDH1A1TSHRCYP2C19MAPTKDM4E
SCHEMBL11286675 0.79 ALDH1A1 (0.42) ALDH1A1LMNAPOLBMAPTHTT
SCHEMBL460383 0.78 TSHR (0.38) ALDH1A1TSHRCYP2C19POLBMAPT
SCHEMBL24956754 0.75 ALDH1A1 (0.44) ALDH1A1TSHRCYP2C19LMNAMAPT
SCHEMBL544100 0.74 ALDH1A1 (0.48) ALDH1A1TSHRCYP2C19KDM4ETDP1
SCHEMBL6226391 0.74 ALDH1A1 (0.48) ALDH1A1TSHRCYP2C19POLBMAPT
SCHEMBL89138 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2390273-B1 DUAL-CURE CURABLE MATERIAL KIT TOKUYAMA DENTAL CORP (JP) 2015-11-04 EP claimed
US-8993652-B2 Dual-cure curable material kit TOKUYAMA DENTAL CORPORATION (JP) 2015-03-31 US claimed
US-20120059079-A1 DUAL-CURE CURABLE MATERIAL KIT TOKUYAMA DENTAL CORPORATION (JP) 2012-03-08 US claimed
EP-2390273-A1 DUAL-CURE CURABLE MATERIAL KIT Tokuyama Dental Corporation (JP) 2011-11-30 EP claimed
US-20110255272-A1 Simulated candle apparatus PRIVAS YVES 2011-10-20 US claimed
EP-2213275-B1 CURABLE COMPOSITION FOR DENTAL APPLICATIONS TOKUYAMA DENTAL CORP (JP) 2019-04-10 EP disclosed
EP-2390273-B1 DUAL-CURE CURABLE MATERIAL KIT TOKUYAMA DENTAL CORP (JP) 2015-11-04 EP disclosed
US-8993652-B2 Dual-cure curable material kit TOKUYAMA DENTAL CORPORATION (JP) 2015-03-31 US disclosed
US-8993652-B2 Dual-cure curable material kit TOKUYAMA DENTAL CORPORATION (JP) 2015-03-31 US disclosed
US-8765837-B2 Dental curable composition TOKUYAMA DENTAL CORPORATION (JP) 2014-07-01 US disclosed
US-20120059079-A1 DUAL-CURE CURABLE MATERIAL KIT TOKUYAMA DENTAL CORPORATION (JP) 2012-03-08 US disclosed
US-20120059079-A1 DUAL-CURE CURABLE MATERIAL KIT TOKUYAMA DENTAL CORPORATION (JP) 2012-03-08 US disclosed
EP-2390273-A1 DUAL-CURE CURABLE MATERIAL KIT Tokuyama Dental Corporation (JP) 2011-11-30 EP disclosed
US-20110255272-A1 Simulated candle apparatus PRIVAS YVES 2011-10-20 US disclosed
US-20100261144-A1 Dental Curable Composition TOKUYAMA DENTAL CORPORATION (JP) 2010-10-14 US disclosed
EP-2213275-A1 CURABLE COMPOSITION FOR DENTAL APPLICATIONS Tokuyama Dental Corporation (JP) 2010-08-04 EP disclosed
WO-2010067790-A1 DUAL-CURE CURABLE MATERIAL KIT 株式会社トクヤマデンタル (JP) 2010-06-17 WO disclosed
US-6822058-B1 POLYMERIZABLE RESIN, PROMOTED PEROXIDE INCLUDES TERTIARY PERESTER, TRANSITION METAL CATALYST, AND AROMATIC TERITIARY AMINE SYNERGIST; THE SHERWIN-WILLIAMS COMPANY 2004-11-23 US disclosed
US-4323348-A Dental compositions BAYER AKTIENGESELLSCHAFT (DE) 1982-04-06 US disclosed
EP-0023685-A2 Dental masses BAYER AG (DE) 1981-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059079-A1 DUAL-CURE CURABLE MATERIAL KIT KIT, DSTYK, H1-5 ALDH1A1 921/4885TSHR 4729/4885CYP2C19 2693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.